Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Vytorin by Year
Vytorin (ezetimibe/simvastatin, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)
Merck Vytorin: $182M in FY2020, down 36.1% from a year earlier. No newer figure appears in the documents we track.
Where the FY2020 figure comes from
“|| Vytorin | 41 | 53 | 39 | 47 | 43 | 182 | -23 | -27”
Source: Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vytorin (ezetimibe/simvastatin, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2020 | Dec 31, 2020 | 182 | -36.1% | Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗ |
| FY2019 | Dec 31, 2019 | 285 | -42.7% | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
| FY2018 | Dec 31, 2018 | 497 | -33.8% | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2017 | Dec 31, 2017 | 751 | -34.2% | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2016 | Dec 31, 2016 | 1,141 | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Breakdown
What makes up vytorin
- Vytorin (ezetimibe/simvastatin, legacy pre-Organon spin-off) — U.S. sales ($M)12 · FY2020
- Vytorin (ezetimibe/simvastatin, legacy pre-Organon spin-off) — International sales ($M)171 · FY2020
- Vytorin (ezetimibe/simvastatin, legacy pre-Organon spin-off) — Worldwide reported growth YoY (%)-36.0% · FY2020
- Vytorin (ezetimibe/simvastatin, legacy pre-Organon spin-off) — Worldwide constant-currency (ex-exchange) growth YoY (%)-34.0% · FY2020
Cite this data
StockData. (2026). Merck Vytorin ($M), annual FY2016–FY2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-vytorin
See every metric in the Merck KPI table. Data updated Oct 26, 2026.